Spots Global Cancer Trial Database for relapsed or refractory acute lymphoblastic leukemia
Every month we try and update this database with for relapsed or refractory acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | NCT01887587 | Relapsed or Ref... Relapsed or Ref... Mixed Phenotype... | MLN9708 Vincristine Doxorubicin Dexamethasone | 18 Years - | Medical College of Wisconsin | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | NCT05292664 | Myelodysplastic... Myelodysplastic... Myelodysplastic... Treatment-Relat... Therapy-Related... Acute Lymphobla... Acute Lymphobla... Lymphoblastic L... Lymphoblastic L... Acute Leukemia ... Acute Leukemia ... | Venetoclax Azacitidine Cytarabine Methotrexate Hydrocortisone Leucovorin Dexamethasone Vincristine Doxorubicin Dexrazoxane Calaspargase Pe... Erwinia asparag... | 1 Year - 40 Years | Dana-Farber Cancer Institute | |
| A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL | NCT03018093 | Relapsed or Ref... | C-CAR-011 | 14 Years - 75 Years | Cellular Biomedicine Group Ltd. | |
| Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT04825496 | Relapsed or Ref... | ssCART-19 Cells Fludarabine Cyclophosphamid... | 18 Years - 65 Years | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | |
| Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT04684147 | Relapsed or Ref... | single dose of ... | 18 Years - 65 Years | Juventas Cell Therapy Ltd. | |
| A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT04230473 | Relapsed or Ref... | single dose of ... | 18 Years - 65 Years | Juventas Cell Therapy Ltd. | |
| Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT04825496 | Relapsed or Ref... | ssCART-19 Cells Fludarabine Cyclophosphamid... | 18 Years - 65 Years | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | NCT05292664 | Myelodysplastic... Myelodysplastic... Myelodysplastic... Treatment-Relat... Therapy-Related... Acute Lymphobla... Acute Lymphobla... Lymphoblastic L... Lymphoblastic L... Acute Leukemia ... Acute Leukemia ... | Venetoclax Azacitidine Cytarabine Methotrexate Hydrocortisone Leucovorin Dexamethasone Vincristine Doxorubicin Dexrazoxane Calaspargase Pe... Erwinia asparag... | 1 Year - 40 Years | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
